ISPOR—the professional society for health economics and outcomes research, announced that its joint ISPOR-FDA Summit 2020 has been redesigned as a completely virtual event that will be held September 29, 2020.Read more
People with kidney diseases are often excluded from clinical trials because of the complexity and high morbidity of kidney disease.
COVID-19 puts people with kidney diseases at a two to sixteen-fold increased risk of severe symptoms.
All investigators should include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19.Read more
Rutgers’ RUCDR Infinite Biologics received an amended emergency use authorization from the FDA late Thursday for the first SARS-CoV-2 coronavirus test that will allow people to collect their own saliva at home and send to a lab for results. The decision follows the FDA’s recent emergency approval to RUCDR Infinite Biologics for the first saliva-based test, which involves health care workers collecting saliva from individuals at testing sites.Read more
Researchers at Beaumont Health have begun enrolling patients in a new clinical study aimed at treating COVID-19 patients with two common drugs.Read more
The labels of drinks marketed to kids do not help parents and other consumers differentiate among fruit juice and sugar-laden, artificially flavored drinks.Read more
The FDA has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency. The new saliva collection method, which RUCDR developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL), will allow for broader population screening than the current method of nose and throat swabs.Read more
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.Read more
The FDA’s announcement Friday to approve convalescent serum therapy as a large-scale clinical trial opened the door for more patients to receive the potentially life-saving gift of a donor’s plasma.Read more
Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient into a critically ill patient. This treatment was fast-tracked to the bedside over the weekend as the death toll in the COVID-19 pandemic soared to more than 2,000 people across the United States, with more than 100,000 Americans sick from the virus.Read more
AACC thanks the FDA for being responsive to the concerns of the clinical laboratory community and amending the coronavirus guidance to allow CMS-certified labs to develop and implement new tests for coronavirus prior to FDA approval.Read more